Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
ZyStor Therapeutics, Inc. is a biotechnology company developing innovative therapeutics that will significantly improve the lives of patients who suffer from genetic disorders known as Lysosomal Storage Diseases. Lysosomal Storage Diseases are a class of more than 40 rare genetic diseases, each caused by a deficiency in a specific lysosomal enzyme. ZyStor Therapeutics is developing enzyme replacement therapies using its novel, proprietary technology, known as Glycosylation Independent Lysosomal Targeting (GILT), which improves the delivery of lysosomal enzymes to clinically significant tissues. ( www.zystor.com )
ZyStor Therapeutics , Inc.
10437 Innovation Drive Suite 100
Milwaukee, Wisconsin 53226-4838
USA
Tel: (414) 727-9777
Fax: (414) 727-9727